Latest Apiam Animal Health (ASX:AHX) News

Apiam Animal Health has secured Foreign Investment Review Board approval for its acquisition by Adamantem Capital, paving the way for a crucial shareholder vote in February.

Apiam Animal Health Limited shareholders are set to vote on a scheme of arrangement offering $0.87 cash per share or a mix of cash and unlisted scrip in a new holding company controlled by Adamantem Capital. The Independent Expert deems the cash offer fair and reasonable, while scrip options carry liquidity and minority risks.

Apiam Animal Health reported a challenging FY25 with underperformance in its core clinical segment but has rebounded strongly in Q1 FY26. The company is now poised for acquisition by Adamantem Capital, offering shareholders a premium cash and scrip deal.

Apiam Animal Health Limited has entered a binding agreement with Adamantem Capital Fund II for a $228.4 million acquisition via a scheme of arrangement, offering shareholders a significant premium and flexible cash or scrip consideration options.

Adamantem Capital Management has completed its due diligence on Apiam Animal Health and extended its exclusivity period to negotiate a potential $0.87 per share acquisition. The deal remains subject to approvals and binding agreements.

Apiam Animal Health posted modest FY25 revenue growth but saw net profit plunge due to asset impairments, while receiving a non-binding acquisition proposal from Adamantem Capital.

Apiam Animal Health posted modest FY25 growth amid challenges in clinical services, launching a Strategic Reset Program and attracting an acquisition proposal from Adamantem Capital.

Apiam Animal Health reported modest revenue growth but a sharp net profit decline in FY25, launching a Strategic Reset program under new leadership. The company also received a $0.88 per share acquisition proposal from Adamantem Capital Management.

Apiam Animal Health has entered a Process Deed granting Adamantem exclusivity to pursue a $0.88 per share acquisition proposal. The Independent Board Committee signals intent to recommend the deal, pending due diligence and shareholder approval.

Apiam Animal Health has received a non-binding indicative proposal from Adamantem Capital Management to acquire the company at $0.88 per share, sparking a potential shift in ownership for the veterinary services leader.

Apiam Animal Health announces the departure of CEO Chris Richards after nine years, appointing Bruce Dixon as interim managing director during the search for a permanent replacement.